Model validity and risk of bias in randomised placebo-controlled trials of individualised homeopathic treatment.

dc.contributor.author

Mathie, Robert T

dc.contributor.author

Van Wassenhoven, Michel

dc.contributor.author

Jacobs, Jennifer

dc.contributor.author

Oberbaum, Menachem

dc.contributor.author

Frye, Joyce

dc.contributor.author

Manchanda, Raj K

dc.contributor.author

Roniger, Helmut

dc.contributor.author

Dantas, Flávio

dc.contributor.author

Legg, Lynn A

dc.contributor.author

Clausen, Jürgen

dc.contributor.author

Moss, Sian

dc.contributor.author

Davidson, Jonathan RT

dc.contributor.author

Lloyd, Suzanne M

dc.contributor.author

Ford, Ian

dc.contributor.author

Fisher, Peter

dc.coverage.spatial

Scotland

dc.date.accessioned

2016-12-01T14:29:26Z

dc.date.issued

2016-04

dc.description.abstract

BACKGROUND: To date, our programme of systematic reviews has assessed randomised controlled trials (RCTs) of individualised homeopathy separately for risk of bias (RoB) and for model validity of homeopathic treatment (MVHT). OBJECTIVES: The purpose of the present paper was to bring together our published RoB and MVHT findings and, using an approach based on GRADE methods, to merge the quality appraisals of these same RCTs, examining the impact on meta-analysis results. DESIGN: Systematic review with meta-analysis. METHODS: As previously, 31 papers (reporting a total of 32 RCTs) were eligible for systematic review and were the subject of study. MAIN OUTCOME MEASURES: For each trial, the separate ratings for RoB and MVHT were merged to obtain a single overall quality designation ('high', 'moderate, "low", 'very low'), based on the GRADE principle of 'downgrading'. RESULTS: Merging the assessment of MVHT and RoB identified three trials of 'high quality', eight of 'moderate quality', 18 of 'low quality' and three of 'very low quality'. There was no association between a trial's MVHT and its RoB or its direction of treatment effect (P>0.05). The three 'high quality' trials were those already labelled 'reliable evidence' based on RoB, and so no change was found in meta-analysis based on best-quality evidence: a small, statistically significant, effect favouring homeopathy. CONCLUSION: Accommodating MVHT in overall quality designation of RCTs has not modified our pre-existing conclusion that the medicines prescribed in individualised homeopathy may have small, specific, treatment effects.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/27062959

dc.identifier

S0965-2299(16)30005-X

dc.identifier.eissn

1873-6963

dc.identifier.uri

https://hdl.handle.net/10161/13042

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Complement Ther Med

dc.relation.isversionof

10.1016/j.ctim.2016.01.005

dc.subject

Individualised homeopathy

dc.subject

Meta-analysis

dc.subject

Model validity

dc.subject

Randomised placebo-controlled trials

dc.subject

Systematic review

dc.subject

Bias (Epidemiology)

dc.subject

Homeopathy

dc.subject

Humans

dc.subject

Placebos

dc.subject

Randomized Controlled Trials as Topic

dc.subject

Risk

dc.title

Model validity and risk of bias in randomised placebo-controlled trials of individualised homeopathic treatment.

dc.type

Journal article

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/27062959

pubs.begin-page

120

pubs.end-page

125

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Psychiatry & Behavioral Sciences

pubs.organisational-group

Psychiatry & Behavioral Sciences, General Psychiatry

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

25

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Compl Therap Med - Mathie MV and RoB - placebo RCTs - 2016.pdf
Size:
1.85 MB
Format:
Adobe Portable Document Format